NKTRNektar Therapeutics
What is the market doing?
The market is leaning against it: in a downtrend (−42% vs 200-day) and a crowded short (+20% of shares).
In a downtrend, below its 50- and 200-day averages. Price is −42% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 22, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 30, 2026, about a week of normal trading to cover. Up 21% since the previous count, up from 20.2% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How NKTR is trading
Nektar Therapeutics is −32% over the past year while the S&P 500 is +16%: 48 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −42%
vs 200-day average · a clear downtrend
- RSI (14)
- 35
RSI (14) · neutral
- Below its 52-week high
- 63%
Below its 52-week high
Details›
- Last close2026-10-23
- $37.21
- 1 monthS&P 500 −0.94%
- −37%
- 1 yearS&P 500 +16%
- −32%
- 5 yearsS&P 500 +86%
- −86%
- vs 50-day average$59.28
- −37%
- 52-week high
- $100.35
- 52-week low
- $35.12
- Annualised volatility
- 144%
- Insider selling, net, 6 monthsForms 3/4/5 to 2026-10-22
- $86K
| Year | Return |
|---|---|
| 2026 (year to date) | −12% |
| 2025 | +203% |
| 2024 | +66% |
| 2023 | −75% |
| 2022 | −83% |
| 2021 | −21% |
| 2020 | −21% |
| 2019 | −34% |
| 2018 | −45% |
| 2017 | +387% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | +5.2% |
| Feb | 10 | 7 of 10 | +8.7% |
| Mar | 10 | 4 of 10 | −2.1% |
| Apr | 10 | 5 of 10 | +3.7% |
| May | 10 | 2 of 10 | −8.1% |
| Jun | 10 | 5 of 10 | +13% |
| Jul | 11 | 6 of 11 | −0.06% |
| Aug | 11 | 5 of 11 | +1.6% |
| Sep | 11 | 5 of 11 | +6.0% |
| Oct | 11 | 3 of 11 | −12% |
| Nov | 10 | 6 of 10 | +9.9% |
| Dec | 10 | 5 of 10 | −3.7% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.